BGT226

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Advanced Solid TumorBreast CancerCancerCowden SyndromeSolid TumorSolid Tumors

Phase 1

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

CompletedNCT00600275

Novartis PharmaceuticalsBreast Cancer, Cowden Syndrome, Solid Tumors

Start: 2007-12-31Updated: 2020-12-17

Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan

TerminatedNCT00742105

Novartis PharmaceuticalsAdvanced Solid Tumor, Cancer, Solid Tumor

Start: 2008-11-17End: 2009-12-22Updated: 2018-09-25